title: Strategies for relapsed peripheral T-cell lymphoma: the tail that wags the curve.
abstract: A 69-year-old woman was referred for further evaluation and management of relapsed angioimmunoblastic T-cell lymphoma. At diagnosis, she received six cycles of dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) and achieved a complete response (CR). Her first surveillance computed tomography scan 3 months later demonstrated enlarging cervical lymphadenopathy. A lymph node excision confirmed relapsed angioimmunoblastic T-cell lymphoma with atypical lymphocytes expressing CD3, CD4, CD10, PD-1, and EBER, with loss of CD5 (Fig 1). A clonal T-cell receptor beta and gamma rearrangement by polymerase chain reaction was identical to that in her initial diagnostic biopsy. At our initial consultation, options for standard as well as investigational therapies were discussed, and HLA typing was initiated. The patient was enrolled onto an investigational phase II study; however, she developed progressive disease after two cycles. She was then treated with romidepsin 14 mg/m(2) administered intravenously for 3 consecutive weeks with 1 week off. After two cycles, she achieved a partial response, and after four additional cycles, she maintained her response without further improvement. We discussed additional treatment options.
authors: Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
authors: Matthew A
authors: MA
authors: Lunning
authors: Alison J
authors: AJ
authors: Moskowitz
authors: Steven
authors: S
authors: Horwitz
mesh_terms: D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D047630:Depsipeptides / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology; D006801:Humans; D060828:Induction Chemotherapy / Q000379:methods*; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D064847:Multimodal Imaging; D018579:Patient Selection; D049268:Positron-Emission Tomography; D011241:Prednisone / Q000008:administration & dosage; D012008:Recurrence; D012720:Severity of Illness Index; D033581:Stem Cell Transplantation; D014057:Tomography, X-Ray Computed; D014184:Transplantation, Homologous; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000903:Antibiotics, Antineoplastic; D047630:Depsipeptides; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; C087123:romidepsin; D011241:Prednisone
references: Blood. 1994 Sep 1;84(5):1361-92
references: 8068936
references: Blood. 2010 Nov 4;116(18):3418-25
references: 20660290
references: Ann Oncol. 2011 Jul;22(7):1608-1613
references: 21252059
references: Haematologica. 2007 Feb;92(2):271-2
references: 17296587
references: J Clin Oncol. 2012 Feb 20;30(6):631-6
references: 22271479
references: J Clin Oncol. 2008 Sep 1;26(25):4124-30
references: 18626005
references: Eur J Cancer. 2012 Nov;48(17):3223-31
references: 22770877
references: J Clin Oncol. 1994 Jun;12(6):1169-76
references: 8201379
references: Eur J Haematol. 2004 Sep;73(3):179-82
references: 15287915
references: Ann Oncol. 2003;14 Suppl 1:i5-10
references: 12736224
references: Ann Oncol. 2004 Oct;15(10):1467-75
references: 15367405
references: J Clin Oncol. 2013 Jan 1;31(1):104-10
references: 23109692
references: Clin Lymphoma. 2005 Jun;6(1):56-60
references: 15989710
references: Leukemia. 2006 Sep;20(9):1533-8
references: 16871285
references: Blood. 2004 Apr 15;103(8):2920-4
references: 15070664
references: Ann Oncol. 2008 May;19(5):958-63
references: 18303032
references: Cancer. 2010 Oct 1;116(19):4541-8
references: 20572046
references: Blood. 2007 Oct 1;110(7):2316-23
references: 17581918
references: Br J Haematol. 2007 Feb;136(3):439-47
references: 17233846
references: J Clin Oncol. 2011 Mar 20;29(9):1182-9
references: 21245435
references: J Clin Oncol. 2008 May 10;26(14):2264-71
references: 18390969
references: Eur J Haematol. 2007 Jul;79(1):32-8
references: 17598836
references: Leuk Lymphoma. 2012 Jun;53(6):1124-1129
references: 22136377
references: J Clin Oncol. 2009 Jan 1;27(1):106-13
references: 19029417
references: J Clin Oncol. 2012 Jun 20;30(18):2190-6
references: 22614995
references: Br J Haematol. 2010 Oct;151(2):159-66
references: 20738307
references: Leuk Lymphoma. 2007 Jan;48(1):97-103
references: 17325852
references: Bone Marrow Transplant. 2007 Aug;40(3):239-43
references: 17530000
references: J Clin Oncol. 2012 Sep 1;30(25):3093-9
references: 22851556
references: Cancer. 2013 Jan 15;119(2):371-9
references: 22833464
references: Ann Oncol. 2011 Jul;22(7):1595-1600
references: 21212158
references: Blood Rev. 2007 Jul;21(4):201-16
references: 17512649
references: Br J Cancer. 1991 Nov;64(5):903-6
references: 1931613
references: Blood. 1991 Apr 1;77(7):1587-92
references: 2009374
references: Ann Oncol. 2010 Apr;21(4):860-863
references: 19887465
references: J Clin Oncol. 2013 Jun 1;31(16):1970-6
references: 23610113